WILMINGTON, Del.--(BUSINESS WIRE)--Results from the EROS real-world retrospective study showed that initiating fixed-dose triple-combination therapy BREZTRI ...

WILMINGTON, Del.--(BUSINESS WIRE)-- Positive high-level results from the Phase III KALOS and LOGOS trials in patients with uncontrolled asthma showed that AstraZeneca ...

AstraZeneca (NASDAQ:AZN) has initiated a Phase 3 study to evaluate the use of inhaled triple-combination therapy Breztri Aerosphere on severe cardiopulmonary outcomes, including death, in people with ...

THARROS is the first-ever prospective trial to investigate the potential of an inhaled triple therapy to reduce cardiopulmonary events, a key driver of mortality, in COPD First patients dosed in ...

In a Breztri commercial that launched a year ago, a man using the AstraZeneca COPD inhaler was able to participate in hiking and other outdoor activities via an RV road trip. In this year’s spot, a ...

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca’s BREZTRI AEROSPHERE TM (budesonide/glycopyrrolate/formoterol fumarate) has been approved in the US for the ...

Approval based on Phase III ETHOS trial which showed a statistically significant reduction in the rate of exacerbations compared with dual-combination therapies ...